GLP-1 medications, specifically semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), work in part by acting on receptors in the brain that regulate hunger
PMDA, 27 March 2023, Accessed 20 November 2023
Eli Lilly has multiple Phase 3 trials expected to complete through late 2026, with FDA approval projected for 2027 to 2028
December 2025: The Judicial Panel on Multidistrict Litigation (JPML) has approved a new group lawsuit for people who experienced vision loss after taking Mounjaro and other GLP-1s
This worrying trend not only bypasses essential medical oversight but raises natural concerns about the safety, authenticity, and effectiveness of these medications
At Wave Aesthetics in Wilmington, NC, we offer Tirzepatide as part of our comprehensive medical weight loss program to help our clients achieve real, sustainable results under professional medical supervision